相关实验视频
Updated: Jan 13, 2026

08:45
Polygraphic Recording Procedure for Measuring Sleep in Mice
Published on: January 25, 2016
25.1K
素受体2激动剂:一种病理生理学方法来治疗1型麻醉症
Zainab Arif1, Erum Siddiqui1, Syeda Fadak Zahra Hujjat2
1Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan.
Annals of medicine and surgery (2012)
|January 7, 2026
概括
麻醉症1型 (NT1) 治疗正在发展. 像TAK-861这样的素受体2激动剂提供了一种恢复自然清醒的新方法,可能成为NT1的第一个疾病修饰疗法.
科学领域:
- 神经学 神经学
- 睡眠医学 睡眠医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 麻醉症1型 (NT1) 是一种神经系统疾病,由素神经元损失引起,导致白天过度的嗜睡和触角症.
- 目前的NT1治疗可以控制症状,但不能解决潜在的素缺乏症.
- 素受体2 (OX2R) 激动剂是一种新的治疗类,向NT1的核心缺陷.
研究的目的:
- 评估TAK-861 (oveporexton) 的疗效和安全性,这是下一代OX2R激动剂,用于治疗1型麻醉症.
- 通过恢复生理觉醒来,评估TAK-861作为疾病修饰疗法的潜力.
主要方法:
- 研究TAK-861的药理动力学和药理动力学的临床试验.
- 对疗效终点的评估,如触角症频率和清醒度.
- 评估安全性和耐受性,重点关注肝脏效应和剂量方便性.
主要成果:
- 塔克-861在减少触觉障碍和改善清醒方面表现出与之前药物相似的疗效.
- TAK-861具有良好的安全性,对肝脏的影响最小.
- 该药物允许方便的每日一次剂量.
结论:
- 作为NT1治疗的安全有效的OX2R激动剂,TAK-861显示出前景.
- 它有可能成为NT1的第一个疾病修饰疗法,改变治疗范式.
- 需要进一步的第三阶段研究来验证这些发现并支持监管批准.
相关概念视频
Sleep-Wake Cycles
2.7K
Sleep is an essential physiological process vital to maintaining overall well-being. The reticular activating system (RAS), a network of neurons in the brainstem, regulates wakefulness and sleep. While it may seem passive, sleep consists of distinct cycles, each with its unique characteristics and functions. Two key sleep phases are non-rapid eye movement (NREM) and rapid eye movement (REM).
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
2.7K
Narcolepsy
482
Narcolepsy is a chronic sleep disorder characterized by pervasive, uncontrolled sleepiness and other sleep disturbances. One of its hallmark symptoms is an abrupt transition to REM sleep upon falling asleep, which causes symptoms typically associated with this phase to occur unexpectedly during wakefulness. These include the following symptoms, which typically last from a minute or two to half an hour.
482
Management of Insomnia
523
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
523
Sedatives and Hypnotics Drugs: Miscellaneous Agents
502
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
502
Drug-Receptor Interaction: Agonist
3.9K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
3.9K
Opioid Receptors: Overview
4.0K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
4.0K

